Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously.
Clinical Cancer Research.
Times cited: 592
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
Times cited: 300
Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro.
Pediatric Blood and Cancer.
Times cited: 54
Accumulation of α- and β-globin messenger RNAs in mouse erythroleukemia cells.
Times cited: 50